Valuation: PolyPid Ltd.

Market Cap 97.4M 85.26M 78.7M 73.41M 138M 9.21B 141M 944M 367M 4.54B 366M 358M 15.83B P/E 2026 *
-3.56x
P/E 2027 * -4.05x
Enterprise Value 97.4M 85.26M 78.7M 73.41M 138M 9.21B 141M 944M 367M 4.54B 366M 358M 15.83B EV / Sales 2026 *
-
EV / Sales 2027 * 7.12x
Free-Float
78.77%
Yield 2026 *
-
Yield 2027 * -
1 day+2.21%
1 week+1.80%
1 month+7.63%
3 months+15.98%
6 months+17.05%
Current year+17.05%
1 week 4.53
Extreme 4.53
5.24
1 month 4.4
Extreme 4.4
5.24
Current year 4.01
Extreme 4.01
5.24
1 year 3.06
Extreme 3.06
5.24
3 years 2.3
Extreme 2.3
12.3
5 years 2.3
Extreme 2.3
289.2
10 years 2.3
Extreme 2.3
583.5
Manager TitleAgeSince
Chief Executive Officer 52 01/07/2022
Director of Finance/CFO 39 -
Chief Operating Officer 48 01/01/2022
Director TitleAgeSince
Director/Board Member 75 01/06/2020
Director/Board Member 74 01/12/2018
Director/Board Member 84 01/04/2008
Date Insider Type Main position Quantity % Market Cap.
03-18Other

Chief Financial Officer

190,513 0.9983%
03-18Other

Chief Technology Officer

280,063 1.4676%
03-18Other

Director

22,460 0.1177%
Change 5-day change 1-year change 3-year change Capi.($)
+2.21%+1.80%+43.91%-53.61% 95.3M
-2.48%+8.34%+53.87%+155.75% 1,097B
-1.76%+6.23%+66.27%+53.44% 622B
-1.05%+7.19%+35.57%+86.77% 449B
+0.83%+4.18%+31.11%+23.88% 334B
-1.38%+3.75%+39.33%+25.04% 294B
+0.30%+2.56%+31.62%+40.64% 286B
-0.10%+2.23%-28.43%-42.77% 213B
+0.44%+4.35%+29.69%+63.10% 195B
+0.01%+1.03%+13.95%+63.93% 157B
Average -0.27%+4.74%+31.69%+41.62% 364.68B
Weighted average by Cap. -1.12%+7.04%+40.91%+77.66%

Financials

2026 *2027 *
Net sales - 13.68M 11.97M 11.05M 10.31M 19.42M 1.29B 19.77M 133M 51.45M 638M 51.38M 50.23M 2.22B
Net income -33.91M -29.68M -27.4M -25.56M -48.16M -3.21B -49.02M -329M -128M -1.58B -127M -125M -5.51B -32.76M -28.67M -26.47M -24.69M -46.52M -3.1B -47.35M -318M -123M -1.53B -123M -120M -5.32B
Net Debt - -
Logo PolyPid Ltd.
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
Employees
72
Date Price Change Volume
30/06/26 $5.080 +2.21% 282,552
29/06/26 $4.970 +4.63% 423,237
26/06/26 $4.750 +3.94% 150,344
25/06/26 $4.570 -3.99% 130,820
24/06/26 $4.760 -4.61% 210,939
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.080USD
Average target price
12.25USD
Spread / Average Target
+141.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PYPD Stock